Background: The novel molecule endocan, which is released by endothelium and is regulated by proangiogenic and proinflammatory cytokines, may have a role in the pathophysiology of Alzheimer disease (AD). The aim of this study was to evaluate the relationship between serum endocan levels and AD. Methods: A total of 134 patients (47 AD, 42 amnestic mild cognitive impairment [aMCI], and 45 control patients) 65 years of age and older were recruited in this study. Cognitive status of the patients was evaluated by performing the Montreal Cognitive Assessment (MOCA) and the Mini-Mental State Examination (MMSE). Serum endocan levels were measured with an enzyme-linked immunosorbent assay kit. Results: Median serum endocan level was significantly higher in AD patients (380.1 ng/mL) than in both aMCI patients (247.7 ng/mL) and controls (277.6 ng/mL; p < 0.01). Serum endocan level had a weak but significant correlation with MMSE and MOCA scores (r = –0.219 and r = –0.232; p = 0.012 and p = 0.01, respectively). Serum endocan level was detected as a factor independently associated with AD. The cutoff serum level of endocan predicting AD was >288.94 ng/mL in receiver operating characteristic curve analysis (area under the curve 0.71, 95% CI 66.7–90.9, sensitivity 80.9%, specificity 59.8%; p < 0.01). Conclusion: Higher serum endocan levels may be associated with the pathogenesis of AD.

Keywords:
Endocan, Alzheimer disease, Pathogenesis
1.
Vagnucci AH Jr, Li WW: Alzheimer’s disease and angiogenesis. Lancet 2003; 361: 605–608.
2.
Dickstein DL, Walsh J, Brautigam H, et al: Role of vascular risk factors and vascular dysfunction in Alzheimer’s disease. Mt Sinai J Med 2010; 77: 82–102.
3.
Montagne A, Nation DA, Pa J, et al: Brain imaging of neurovascular dysfunction in Alzheimer’s disease. Acta Neuropathol 2016; 131: 687–707.
4.
Thirumangalakudi L, Samany PG, Owoso A, et al: Angiogenic proteins are expressed by brain blood vessels in Alzheimer’s disease. J Alzheimers Dis 2006; 10: 111–118.
5.
Yoon KH, Kim SY, Moon YS, et al: The relationship between serum endocan levels and depression in Alzheimer’s disease. Dis Markers 2016; 2016: 8254675.
6.
Rocchi A, Orsucci D, Tognoni G, et al: The role of vascular factors in late-onset sporadic Alzheimer’s disease. Genetic and molecular aspects. Curr Alzheimer Res 2009; 6: 224–237.
7.
Tarkowski E, Issa R, Sjogren M, et al: Increased intrathecal levels of the angiogenic factors VEGF and TGF-β in Alzheimer’s disease and vascular dementia. Neurobiol Aging 2002; 23: 237–243.
8.
Sarrazin S, Adam E, Lyon M, et al: Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 2006; 1765: 25–37.
9.
Petersen RC, Smith GE, Waring SC, et al: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303–308.
10.
McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939–944.
11.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 5. American Psychiatric Association, 2013.
12.
Reisberg B: Functional assessment staging (FAST). Psychopharmacol Bull 1988; 24: 653–659.
13.
Arik G, Varan HD, Yavuz BB, et al: Validation of Katz index of independence in activities of daily living in Turkish older adults. Arch Gerontol Geriatr 2015; 61: 344–350.
14.
Graf C: The Lawton Instrumental Activities of Daily Living (IADL) scale. Medsurg Nurs 2009; 18: 315–316.
15.
Marc LG, Raue PJ, Bruce ML: Screening performance of the 15-item geriatric depression scale in a diverse elderly home care population. Am J Geriatr Psychiatry 2008; 16: 914–921.
16.
Rubenstein LZ, Harker JO, Salva A, et al: Screening for undernutrition in geriatric practice: developing the short-form Mini-Nutritional Assessment (MNA-SF). J Gerontol A Biol Sci Med Sci 2001; 56:M366–M372.
17.
Folstein MF, Folstein SE, McHugh PR: “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–198.
18.
Kaya Y, Aki OE, Can UA, et al: Validation of Montreal Cognitive Assessment and discriminant power of Montreal Cognitive Assessment subtests in patients with mild cognitive impairment and Alzheimer dementia in Turkish population. J Geriatr Psychiatry Neurol 2014; 27: 103–109.
19.
Nasreddine ZS, Phillips NA, Bedirian V, et al: The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695–699.
20.
Ertem AG, Unal S, Acar B, et al: Endocan: endothelial dysfunction, inflammation, or both? Angiology 2017; 68: 79.
21.
Arpaci D, Karakece E, Tocoglu AG, et al: Endocan, TGF-β, and ADMA as risk factors for endothelial dysfunction and possible vascular disease in patients with subclinical hypothyroidism. Ann Clin Lab Sci 2016; 46: 601–607.
22.
Ozalper V, Kara M, Tanoglu A, et al: Evaluation of endothelial dysfunction in patients with familial Mediterranean fever: the relationship between the levels of asymmetric dimethylarginine and endocan with carotid intima-media thickness and endothelium-dependent vasodilation. Clin Rheumatol 2017; 36: 2071–2077.
23.
Petersen RC: Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256: 183–194.
24.
Yilmaz MI, Siriopol D, Saglam M, et al: Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int 2014; 86: 1213–1220.
25.
Jiang H, Fu XG, Chen YT: Serum level of endothelial cell-specific molecule-1 and prognosis of colorectal cancer. Genet Mol Res 2015; 14: 5519–5526.
26.
Scherpereel A, Depontieu F, Grigoriu B, et al: Endocan, a new endothelial marker in human sepsis. Crit Care Med 2006; 34: 532–537.
27.
Grigoriu BD, Depontieu F, Scherpereel A, et al: Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res 2006; 12: 4575–4582.
28.
Liu N, Zhang LH, Du H, et al: Overexpression of endothelial cell specific molecule-1 (ESM-1) in gastric cancer. Ann Surg Oncol 2010; 17: 2628–2639.
29.
Balta I, Balta S, Demirkol S, et al: Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol 2013; 169: 1066–1070.
30.
Balta I, Balta S, Koryurek OM, et al: Serum endocan levels as a marker of disease activity in patients with Behcet disease. J Am Acad Dermatol 2014; 70: 291–296.
31.
Xiong C, Zhao ZW, Chen ZY, et al: Elevated human endothelial cell-specific molecule-1 level and its association with coronary artery disease in patients with hypertension. J Investig Med 2015; 63: 867–870.
32.
Balta S, Mikhailidis DP, Demirkol S, et al: Endocan: a novel inflammatory indicator in cardiovascular disease? Atherosclerosis 2015; 243: 339–343.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.